Financial Performance - The company reported a net loss of $81.0 million for the three months ended March 31, 2023, compared to a net loss of $94.8 million for the same period in 2022, with an accumulated deficit of $551.6 million as of March 31, 2023 [84]. - Total revenue for the three months ended March 31, 2023, increased by $4.8 million to $5.6 million compared to $0.8 million in the same period in 2022, primarily due to increased product revenue from PYRUKYND® [101]. - Total operating expenses decreased by $5.8 million to $96.2 million for the three months ended March 31, 2023, compared to $102.0 million in 2022, driven by a reduction in selling, general and administrative expenses and research and development expenses [102]. - Research and development expenses totaled $67.3 million for the three months ended March 31, 2023, down from $70.1 million in 2022, reflecting a decrease in direct and indirect expenses [103]. - Interest income for the three months ended March 31, 2023, increased to $8.1 million, up from $0.7 million in 2022, primarily due to rising interest rates [105]. - The net loss for the three months ended March 31, 2023, decreased to $81.0 million from $94.8 million in 2022, attributed to increased revenue and lower operating expenses [106]. - Net cash used in operating activities for the three months ended March 31, 2023, was $95.2 million, slightly improved from $97.7 million in the same period of 2022 [111]. - Cash provided by investing activities was $57.6 million for the three months ended March 31, 2023, compared to a cash outflow of $26.6 million in the same period of 2022 [112]. - As of March 31, 2023, the company's cash, cash equivalents, and marketable securities balance was $1.0 billion, down from $1.1 billion at the end of 2022 [121]. Product Development and Clinical Trials - PYRUKYND® received FDA approval on February 17, 2022, for treating hemolytic anemia in adults with PK deficiency, leading to the generation of product revenue [85]. - PYRUKYND® is currently being evaluated in clinical trials for thalassemia, sickle cell disease, and pediatric patients with PK deficiency [92]. - The company is conducting multiple clinical trials for PYRUKYND®, including phase 3 trials ENERGIZE and ENERGIZE-T, which have closed screening for patient enrollment [93]. - The phase 2 portion of the RISE UP trial for PYRUKYND® has been fully enrolled, with data expected to be announced by mid-year 2023 [93]. - AG-946, a novel PK activator, is currently in a phase 1 trial with healthy volunteers and SCD patients, with a phase 2a study initiated in adults with LR MDS expected to complete enrollment by year-end 2023 [95]. - The company expects to file an IND for a PAH stabilizer for the treatment of PKU by year-end 2023 [96]. Business Transactions and Revenue - The sale of the oncology business to Servier Pharmaceuticals was completed on March 31, 2021, for approximately $1.8 billion in cash, with additional contingent payments based on future drug approvals [79]. - The company recognized income of $127.9 million from the sale of future contingent payments related to its oncology business in 2022 [81]. - The company completed the sale of its oncology business to Servier for approximately $1.8 billion in cash, with additional potential payments of $200 million and royalties of 5% and 15% on U.S. net sales of TIBSOVO® and vorasidenib, respectively [108][110]. - The company retains rights to potential milestone payments and royalties from Servier if vorasidenib is approved by the FDA [81]. - The company is focused on expanding its intellectual property portfolio and may pursue collaborations and licensing arrangements for pipeline growth [84]. Future Outlook and Expenses - The company expects significant increases in research and development expenses as clinical development activities for PYRUKYND® and AG-946 progress [88]. - The company anticipates an increase in selling, general and administrative expenses to support ongoing research and commercialization activities related to PYRUKYND® and other product candidates [98]. - The company expects expenses to increase as it continues research and development, clinical trials, and commercialization of its product candidates, including PYRUKYND® [114]. - Future capital requirements will depend on factors such as revenue from commercial sales of PYRUKYND® and contingent consideration from Servier [115][116]. - The company plans to finance cash needs primarily through existing cash, potential milestone payments, and royalties from Servier if vorasidenib is approved [118]. - The company may pursue opportunistic debt offerings and equity transactions to raise additional capital, which could dilute existing stockholder interests [119]. Market Risks - The company is exposed to market risks related to interest rates and foreign currency exchange rates, with no current hedging strategies in place [121][122].

[Business Overview](index=6&type=section&id=Item%201.%20Business) [Company Profile and Strategy](index=6&type=section&id=General) Agios Pharmaceuticals refocused on rare diseases after selling its oncology business for approximately **$1.8 billion**, aiming for cash-flow positivity by 2026 with its lead product PYRUKYND® and a refined research strategy - On March 31, 2021, the company sold its oncology business to Servier for approximately **$1.8 billion** in cash, plus potential **$200.0 million** milestone and royalties on TIBSOVO® and vorasidenib sales[21](index=21&type=chunk) - In October 2022, Agios sold TIBSOVO® royalty rights for **$127.9 million**, retaining vorasidenib milestone and royalty rights[23](index=23&type=chunk) - The company's 2026 strategic vision includes establishing a hematology franchise with PYRUKYND® approvals, portfolio expansion, and achieving **cash-flow positivity**[31](index=31&type=chunk) - In May 2022, the company restructured its research to focus on late-stage programs and in-licensing, reducing 45 roles and projecting annual cost savings of **$40-$50 million** from 2023-2026[24](index=24&type=chunk)[26](index=26&type=chunk) [Development Pipeline](index=9&type=section&id=Our%20Development%20Programs) Agios's pipeline, focused on cellular metabolism and hematology, is led by PYRUKYND® for PK deficiency, thalassemia, and sickle cell disease, alongside AG-946 for MDS and a preclinical PKU program [PYRUKYND® (mitapivat)](index=12&type=section&id=PYRUKYND%C2%AE%20(mitapivat)%3A%20First-in-Class%20PK%20Activator) PYRUKYND®, an oral PK activator, received 2022 approvals for PK deficiency and is in pivotal trials for thalassemia, sickle cell disease, and pediatric PK deficiency - PYRUKYND® received marketing approval in the U.S. (Feb 2022), EU (Nov 2022), and Great Britain (Dec 2022) for adults with PK deficiency[52](index=52&type=chunk) PYRUKYND® Clinical Trial Status | Trial Name | Indication | Phase | Status / Next Milestone | | :--- | :--- | :--- | :--- | | **ENERGIZE** | Non-transfusion-dependent Thalassemia | 3 | Enrolling; expect to complete enrollment by mid-year 2023 | | **ENERGIZE-T** | Transfusion-dependent Thalassemia | 3 | Enrolling; expect to complete enrollment by mid-year 2023 | | **RISE UP** | Sickle Cell Disease (SCD) | 2/3 | Phase 2 fully enrolled; data and Phase 3 initiation decision expected by mid-year 2023 | | **ACTIVATE-kids / kidsT** | Pediatric PK Deficiency | 3 | Enrolling; expect to enroll at least half of patients by year-end 2023 | [AG-946 and Other Programs](index=13&type=section&id=AG-946%20and%20Other%20Programs) Agios is developing AG-946 for LR MDS with Phase 2a enrollment expected by year-end 2023, and plans an IND filing for a PKU PAH stabilizer by year-end 2023 - A Phase 2a study of AG-946 in adults with LR MDS is underway, with enrollment expected to complete by **year-end 2023**[55](index=55&type=chunk) - The company plans to file an IND for its PAH stabilizer program for PKU by **year-end 2023**[56](index=56&type=chunk) [Intellectual Property](index=13&type=section&id=Intellectual%20Property) Agios protects its PK activator program, including PYRUKYND® and AG-946, with 11 issued U.S. and 190 foreign patents expiring from 2030 to 2042 - As of February 1, 2023, the PK activator program patent portfolio includes **11 issued U.S. patents** and **190 issued foreign patents**[59](index=59&type=chunk) - Patents covering the PK activator program have statutory expiration dates ranging from at least **2030 to 2042**, with potential for extensions[60](index=60&type=chunk) [Competition](index=15&type=section&id=Competition) Agios faces intense competition in rare diseases, particularly for hemolytic anemias and PKU, from major pharmaceutical companies and developers of gene therapies and other PK activators - Key competitors include **BMS, BioMarin, bluebird bio, Merck, Novartis, Pfizer, Rocket Pharma, and Vertex**[67](index=67&type=chunk) - Specific competitive threats include gene therapies for PK deficiency (Rocket Pharma) and SCD (Vertex), and a PKR activator from Novo Nordisk for hemolytic anemias[68](index=68&type=chunk) [Manufacturing and Supply](index=16&type=section&id=Manufacturing%20and%20Supply%20Chain) Agios relies entirely on third-party contract manufacturers for all supply, with redundant raw material and API sources for PYRUKYND® but no redundant finished drug product supply - The company relies on **third parties for all manufacturing** and has no plans to establish its own facilities[73](index=73&type=chunk) - For PYRUKYND®, Agios has redundant supply for raw materials and API but not for the final drug product, though it maintains a safety stock[75](index=75&type=chunk) [Government Regulation](index=16&type=section&id=Government%20Regulation%20and%20Product%20Approvals) Agios's products are subject to extensive government regulation, including rigorous testing, manufacturing, and approval processes, with the regulatory landscape impacted by healthcare reforms like the U.S. Inflation Reduction Act - The U.S. drug approval process involves preclinical testing, IND filing, Phase 1-3 clinical trials for safety and efficacy, and NDA submission to the FDA[78](index=78&type=chunk) - The Inflation Reduction Act of 2022 (IRA) will impact Medicare pricing through negotiations for high-cost drugs starting in **2026** and inflation-based rebates, potentially affecting future profitability[149](index=149&type=chunk)[150](index=150&type=chunk) - In the EU, marketing authorization can be obtained via centralized, decentralized, or mutual recognition procedures, with the centralized procedure compulsory for orphan drugs like PYRUKYND®[160](index=160&type=chunk)[161](index=161&type=chunk) [Human Capital](index=35&type=section&id=Employees%20and%20Human%20Capital) As of December 31, 2022, Agios had **393 U.S.-based employees**, with a 59% female and 31% ethnically diverse workforce, supported by a flexible work policy - As of December 31, 2022, the company had **389 full-time** and **4 part-time employees**[178](index=178&type=chunk) - The workforce is **59% female** and **31% ethnically diverse**, with continued emphasis on Black and Latino representation[181](index=181&type=chunk) - The company has a flexible work policy, with **67% of 2022 new hires** choosing to work remotely[184](index=184&type=chunk) [Risk Factors](index=39&type=section&id=Item%201A.%20Risk%20Factors) [Risks Related to Product Development and Commercialization](index=39&type=section&id=Risks%20Related%20to%20the%20Discovery%2C%20Development%2C%20and%20Commercialization%20of%20our%20Products%20and%20Product%20Candidates) Agios's success depends on PYRUKYND® commercialization and pipeline advancement, facing risks of clinical trial failures, patient enrollment challenges, intense competition, market acceptance issues, and ongoing COVID-19 disruptions - The company's prospects are substantially harmed if it does not successfully commercialize **PYRUKYND®**, its first approved rare disease product[191](index=191&type=chunk) - The company depends heavily on its clinical product candidates, with trials facing risks of efficacy failure, side effects, or enrollment challenges, especially for orphan diseases[193](index=193&type=chunk)[196](index=196&type=chunk) - The COVID-19 pandemic may continue to disrupt clinical trials, regulatory activities, and commercial infrastructure[200](index=200&type=chunk)[201](index=201&type=chunk) - PYRUKYND® and other candidates face substantial competition from companies like **Rocket Pharma, Vertex, Novo Nordisk, and Pfizer** developing therapies for the same indications[209](index=209&type=chunk)[223](index=223&type=chunk) [Financial and Operational Risks](index=48&type=section&id=Risks%20Related%20to%20Our%20Financial%20Position) As a smaller, rare disease-focused company post-oncology sale, Agios faces financial risks from historical operating losses, potential need for dilutive capital, uncertain milestone payments, cybersecurity breaches, and stringent data privacy compliance - As a smaller company focused on rare diseases after the oncology sale, Agios is more susceptible to changing market conditions[251](index=251&type=chunk)[253](index=253&type=chunk) - The company has a history of operating losses, with a net loss of **$231.8 million** in 2022, and profitability depends on successful commercialization[18](index=18&type=chunk)[259](index=259&type=chunk) - The receipt of a **$200.0 million** milestone payment and future royalties from Servier for vorasidenib is contingent on uncertain regulatory approval and commercial success[264](index=264&type=chunk)[265](index=265&type=chunk) - The company's internal systems are vulnerable to cyber incidents, and it is subject to stringent data privacy laws (HIPAA, GDPR, CCPA) with significant non-compliance penalties[236](index=236&type=chunk)[240](index=240&type=chunk) [Risks Related to Third Parties and Intellectual Property](index=52&type=section&id=Risks%20Related%20to%20Our%20Dependence%20on%20Third%20Parties) Agios heavily relies on third-party CROs and CMOs, posing operational risks, and its success depends on robust intellectual property protection, facing risks of patent infringement and validity challenges - The company relies on third-party CROs for clinical trials and is responsible for their cGCP compliance, as failure could render data unreliable[269](index=269&type=chunk)[271](index=271&type=chunk) - Agios depends on third-party manufacturers for all product supply, with performance failures, disruptions, or cGMP non-compliance risking development and commercialization delays[276](index=276&type=chunk)[277](index=277&type=chunk)[279](index=279&type=chunk) - Successful commercialization depends on obtaining and maintaining patent protection, which may be challenged, invalidated, or circumvented by competitors[285](index=285&type=chunk)[291](index=291&type=chunk)[292](index=292&type=chunk) [Regulatory and Legal Risks](index=57&type=section&id=Risks%20Related%20to%20Regulatory%20Approval%20of%20Our%20Product%20Candidates%20and%20Other%20Legal%20Compliance%20Matters) Agios faces significant regulatory and legal risks, including uncertain and costly marketing approvals, pricing and reimbursement pressures intensified by healthcare reforms, and strict compliance with anti-kickback and fraud laws - The regulatory approval process is uncertain, potentially delaying or preventing commercialization, as authorities have discretion and may require additional costly trials[301](index=301&type=chunk)[304](index=304&type=chunk) - Even if approved, products may face unfavorable pricing and reimbursement, intensified by the Inflation Reduction Act and other healthcare reforms, harming the business[332](index=332&type=chunk)[338](index=338&type=chunk)[346](index=346&type=chunk) - The company is subject to strict healthcare laws, including the federal Anti-Kickback Statute and False Claims Act, risking criminal sanctions, civil penalties, and reputational harm[326](index=326&type=chunk)[327](index=327&type=chunk) [Financial Condition and Results of Operations (MD&A)](index=76&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) [Overview of Financial Performance](index=76&type=section&id=Financial%20Operations%20Overview) Agios reported a **$231.8 million net loss** in 2022, a shift from **$1.6 billion net income** in 2021 due to the oncology business sale, reflecting its rare disease focus with initial PYRUKYND® revenues and increased R&D Consolidated Statements of Operations Data (in thousands) | (In thousands) | 2022 | 2021 | 2020 | | :--- | :--- | :--- | :--- | | **Total Revenue** | $14,240 | $— | $— | | **Total Operating Expenses** | $403,287 | $378,418 | $335,916 | | **Net Loss from Continuing Operations** | $(231,801) | $(356,510) | $(329,305) | | **Net Income from Discontinued Operations, Net of Tax** | $— | $1,961,225 | $1,935 | | **Net (Loss) Income** | **$(231,801)** | **$1,604,715** | **$(327,370)** | [Results of Operations (2020-2022)](index=84&type=section&id=Results%20of%20Operations) In 2022, total revenue reached **$14.2 million** from PYRUKYND® launch, R&D expenses increased to **$279.9 million**, and a **$127.9 million gain** from TIBSOVO® royalty rights reduced net loss from continuing operations to **$231.8 million** Revenue Breakdown (in thousands) | (In thousands) | 2022 | 2021 | | :--- | :--- | :--- | | Product Revenue, Net | $11,740 | $— | | Milestone Revenue | $2,500 | $— | | **Total Revenue** | **$14,240** | **$—** | Research and Development Expenses (in thousands) | (In thousands) | 2022 | 2021 | 2020 | | :--- | :--- | :--- | :--- | | PK Activator (PYRUKYND®) | $83,271 | $73,999 | $48,669 | | Novel PK Activator (AG-946) | $15,747 | $10,658 | $8,378 | | Other Research and Platform Programs | $26,837 | $22,959 | $13,790 | | Indirect R&D Expenses | $154,055 | $149,357 | $149,974 | | **Total R&D Expense** | **$279,910** | **$256,973** | **$220,811** | - In 2022, the company recognized a **$127.9 million gain** on the sale of its rights to future TIBSOVO® royalty payments to Sagard[409](index=409&type=chunk)[460](index=460&type=chunk) [Liquidity and Capital Resources](index=86&type=section&id=Liquidity%20and%20Capital%20Resources) As of December 31, 2022, Agios held **$1.1 billion** in cash and equivalents, bolstered by the oncology sale, with management expecting sufficient capital to reach cash-flow positivity without additional equity - As of December 31, 2022, the company had cash, cash equivalents, and marketable securities of **$1.1 billion**[470](index=470&type=chunk)[492](index=492&type=chunk) Cash Flow Summary (in thousands) | (In thousands) | 2022 | 2021 | 2020 | | :--- | :--- | :--- | :--- | | Net Cash Used in Operating Activities | $(309,478) | $(407,320) | $(290,759) | | Net Cash Provided by Investing Activities | $243,261 | $1,248,778 | $75,746 | | Net Cash Provided by (Used in) Financing Activities | $2,350 | $(765,768) | $261,518 | - The company expects existing cash and anticipated revenues will enable it to execute its operating plan to **cash-flow positivity** without additional equity[483](index=483&type=chunk) [Contractual Obligations](index=89&type=section&id=Contractual%20Obligations) As of December 31, 2022, Agios had approximately **$109.4 million** in contractual obligations, primarily **$99.2 million** for operating leases, alongside manufacturing and service arrangements Contractual Obligations (in thousands) | (In thousands) | Total | Less than 1 year | 1-3 years | 3-5 years | More than 5 years | | :--- | :--- | :--- | :--- | :--- | :--- | | Operating Lease Obligations | $99,203 | $16,651 | $38,167 | $40,906 | $3,479 | | Manufacturing Arrangements | $904 | $301 | $603 | $— | $— | | Service Arrangements | $9,300 | $1,860 | $3,720 | $3,720 | $— | [Financial Statements and Notes](index=90&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) [Consolidated Financial Statements](index=102&type=section&id=Consolidated%20Financial%20Statements) The audited consolidated financial statements for 2022 reflect Agios's financial position, including **$1.1 billion** in cash and equivalents, and the reclassification of the oncology business as a discontinued operation Consolidated Balance Sheet Data (in thousands) | (In thousands) | Dec 31, 2022 | Dec 31, 2021 | | :--- | :--- | :--- | | **Assets** | | | | Cash, Cash Equivalents & Marketable Securities | $1,097,000 | $1,300,000 | | Total Assets | $1,238,718 | $1,437,736 | | **Liabilities & Equity** | | | | Total Liabilities | $137,904 | $145,761 | | Total Stockholders' Equity | $1,100,814 | $1,291,975 | [Key Notes to Financial Statements](index=107&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) Key notes detail the **$1.98 billion** pre-tax gain from the oncology business sale, PYRUKYND® product revenue, the **$1.2 billion** share repurchase program, and the **$296.0 million** valuation allowance against deferred tax assets - **Discontinued Operations (Note 15):** The March 31, 2021, sale of the oncology business to Servier resulted in a pre-tax gain of **$1,989.1 million**, with historical results reported separately[682](index=682&type=chunk)[684](index=684&type=chunk)[686](index=686&type=chunk) - **Product Revenue (Note 8):** For 2022, gross product sales were reduced by **$1.5 million** for adjustments, resulting in net revenue of **$11.7 million**[639](index=639&type=chunk)[641](index=641&type=chunk) - **Share Repurchase Program (Note 14):** As of Dec 31, 2022, the company repurchased **16.2 million shares** for **$802.5 million** under its **$1.2 billion** authorization, with the program currently paused[678](index=678&type=chunk)[679](index=679&type=chunk)[680](index=680&type=chunk) - **Income Taxes (Note 11):** The company maintains a full valuation allowance of **$296.0 million** against its deferred tax assets as of Dec 31, 2022, due to uncertainty of realization[667](index=667&type=chunk)[670](index=670&type=chunk) [Other Information](index=74&type=section&id=PART%20II%20Other%20Information) [Market for Common Equity and Shareholder Matters](index=74&type=section&id=Item%205.%20Market%20for%20Registrant%27s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) Agios's common stock trades on Nasdaq under "AGIO"; the company has never paid dividends and has paused its **$1.2 billion** share repurchase program after repurchasing **$802.5 million** in shares - A share repurchase program of up to **$1.2 billion** was authorized in March 2021, with **16.2 million shares** repurchased for **$802.5 million** as of December 31, 2022[398](index=398&type=chunk)[399](index=399&type=chunk) - The company has paused share repurchases to prioritize capital for development and business opportunities[400](index=400&type=chunk) [Corporate Governance and Controls](index=90&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management and PricewaterhouseCoopers LLP concluded that Agios's disclosure controls and internal control over financial reporting were effective as of December 31, 2022 - Management concluded that the company's disclosure controls and procedures were **effective** as of December 31, 2022[497](index=497&type=chunk) - Management and PricewaterhouseCoopers LLP concluded that the company's internal control over financial reporting was **effective** as of December 31, 2022[501](index=501&type=chunk)

Business Transactions - The company completed the sale of its oncology business to Servier Pharmaceuticals for approximately $1.8 billion in cash, with potential additional payments of $200 million and royalties of 5% and 15% on U.S. net sales of TIBSOVO® and vorasidenib, respectively[10]. - The company received approximately $1.8 billion in cash from the sale of its oncology business to Servier, with additional contingent payments based on regulatory approvals and sales performance[111]. - The company has classified the results of its oncology business as discontinued operations following its sale in Q1 2021[172]. Product Development and Approvals - PYRUKYND® (mitapivat) was approved by the FDA in February 2022 for treating hemolytic anemia in adults with pyruvate kinase deficiency, with a commercial launch expected in Q1 2022[11]. - The company is developing AG-946, a next-generation PK activator, for potential treatment of hemolytic anemias and other indications, including sickle cell disease[11]. - PYRUKYND® has been approved by the FDA for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, with ongoing regulatory review in the EU[28]. - The company submitted a Marketing Authorization Application (MAA) to the EMA in June 2021 for the same indication in the European Union[95]. - The company expects to initiate two phase 3 trials of PYRUKYND® in pediatric patients with PK deficiency in mid-2022[163]. - AG-946, a next-generation PKR activator, is currently in a phase 1 trial with healthy volunteers, and the SCD patient cohort is expected to begin in the first half of 2022[163]. Financial Performance - The company reported a net income of $1,604.7 million for the year ended December 31, 2021, primarily due to the sale of its oncology business to Servier on March 31, 2021[160]. - The accumulated deficit as of December 31, 2021, was $238.8 million, with net losses of $327.4 million and $411.5 million for the years ended December 31, 2020, and 2019, respectively[160]. - PYRUKYND® revenue for 2021 was $73.999 million, up from $48.669 million in 2020, representing a 52% increase[175]. - Total operating expenses increased by $42.5 million in 2021 compared to 2020, primarily due to a $36.2 million increase in research and development expenses[174]. Research and Development - The company aims to achieve cash flow positivity and advance at least five internally discovered molecules in clinical development spanning at least ten indications over the next five years[14]. - The company expects research and development costs related to its genetically defined disease portfolio to increase significantly as product candidate development programs progress[161]. - The company has built its U.S. commercial infrastructure to support the launch of PYRUKYND® and is exploring partnership opportunities for commercialization outside the U.S.[161]. Regulatory and Compliance - The company must navigate extensive regulatory processes for drug approval, which require substantial time and financial resources[39]. - The FDA requires compliance with post-approval regulatory requirements, including reporting adverse reactions and manufacturing problems[54]. - The company emphasizes the importance of maintaining its proprietary and intellectual property position through effective patent claims and enforcement[35]. - The company is committed to identifying and qualifying additional manufacturers for its product candidates prior to submitting a New Drug Application (NDA) to the FDA[38]. Market and Competitive Landscape - The company faces competition from major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Merck, and Pfizer, among others, in the development of therapies for genetic diseases[36]. - The company’s ability to compete may be affected by the speed at which competitors obtain regulatory approvals for their medicines[36]. - The commercial success of PYRUKYND® will depend significantly on third-party payor coverage and reimbursement, which can vary widely among payors[129]. Employee and Workplace Culture - The company had 390 full-time employees and 2 part-time employees as of December 31, 2021, with 120 holding advanced degrees[88]. - 59% of the workforce were women, and 30% were ethnically diverse as of December 31, 2021[88]. - The company emphasizes flexibility, psychological safety, and deliberate development in its workplace culture[88]. Risks and Challenges - The company faces challenges in patient enrollment for clinical trials due to the ongoing COVID-19 pandemic, which may delay regulatory approvals[97]. - The company may experience increased development costs and potential abandonment of clinical trials if sufficient patient enrollment is not achieved[97]. - The company is exposed to risks of fraud or misconduct by third parties involved in its clinical trials and research activities[117]. Future Outlook - Future capital requirements will depend on various factors, including revenue from PYRUKYND® and the timing of regulatory approvals[109]. - The company anticipates prioritizing capital allocation towards accelerating development programs and pursuing complementary business opportunities[180]. - The company expects to incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution for PYRUKYND® if marketing approval is obtained[186].

Oncology Business Sale - The company is selling its oncology business to Servier for $1.8 billion in cash, with potential additional payments of $200 million upon FDA approval of vorasidenib[11]. - The oncology business sale is expected to be completed by the end of Q1 or beginning of Q2 2021, subject to regulatory approvals[12]. - The transaction is subject to stockholder approval and regulatory approvals, which may delay or prevent completion[134]. - The anticipated sale of the oncology business to Servier is expected to provide sufficient capital to fund operations through major catalysts and achieve cash-flow positivity without the need for additional equity[142]. - The oncology business sale will result in a smaller, less diversified company, increasing susceptibility to market fluctuations related to GDDs[198]. Focus on Genetically Defined Diseases (GDDs) - The company plans to focus on genetically defined diseases (GDDs) post-sale, which may increase susceptibility to market fluctuations due to reduced diversification[12]. - The lead product candidate in the GDD portfolio, mitapivat, is being evaluated for the treatment of pyruvate kinase deficiency, thalassemia, and sickle cell disease[16]. - The company aims to advance at least five internally discovered molecules in clinical development across ten indications[17]. - The company is developing small molecule therapies for genetically defined diseases (GDDs), with a focus on conditions that have significant unmet medical needs and potential for reversible damage[25]. - The company’s approach to GDDs includes developing mechanistically specific small molecules with potential disease-modifying effects rather than palliative care[25]. Clinical Development and Trials - The company expects to submit IND applications every 12-24 months to maintain a robust research pipeline[17]. - The company aims to progress drug candidates into phase 1 clinical trials by selecting patients based on specific biomarkers, enhancing the probability of success in drug development[26]. - Ongoing clinical trials for ivosidenib include a phase 3 trial combining it with VIDAZA® in newly diagnosed AML patients, which is currently enrolling[37]. - The ClarIDHy phase 3 trial for ivosidenib in cholangiocarcinoma has completed enrollment, with plans to file an sNDA with the FDA in Q1 2021[38]. - The DRIVE PK trial for mitapivat has completed enrollment, focusing on adult, transfusion-independent patients with PK deficiency[48]. Financial Performance - The company incurred net losses of $327.4 million, $411.5 million, and $346.0 million for the years ended December 31, 2020, 2019, and 2018, respectively, with an accumulated deficit of $1,843.5 million as of December 31, 2020[141]. - Total revenue for 2020 was $203.196 million, an increase from $117.912 million in 2019[194]. - Total cost and expenses for 2020 were $519.345 million, compared to $544.245 million in 2019[194]. - Net loss for 2020 was $327.370 million, down from a net loss of $411.472 million in 2019[194]. - Cash, cash equivalents, and marketable securities at year-end 2020 totaled $670.537 million, down from $717.806 million in 2019[194]. Regulatory Environment - The approval process for new drugs in the U.S. requires substantial time and financial resources, including preclinical testing and submission of a New Drug Application (NDA)[73]. - The FDA requires a 30-day waiting period after filing an Investigational New Drug (IND) application before clinical trials can commence, allowing for review of potential health risks to human subjects[76]. - The FDA may require the development of Risk Evaluation and Mitigation Strategies (REMS) as a condition of NDA approval to ensure product benefits outweigh potential risks[82]. - The FDA has established designations such as Fast Track, Breakthrough Therapy, and Priority Review to expedite the review of products addressing serious medical needs, potentially reducing review times from 10 months to 6 months[83]. - The FDA conducts pre-approval inspections of manufacturing facilities and clinical sites to ensure compliance with cGMP and GCP before approving an NDA[81]. Market Competition - The pharmaceutical and biotechnology industries are characterized by intense competition, with major competitors including AbbVie, Novartis, and Pfizer[67]. - The competitive landscape includes a variety of therapies for hematologic malignancies and genetically defined diseases, with many competitors having greater financial resources[67]. - The company faces competition from both established therapies and new medicines in development, which may provide significant competition for its product candidates[68]. - Competition from major pharmaceutical and biotechnology companies poses a risk, as they may develop products more effectively or rapidly than the company[152]. - The company may face challenges in achieving market acceptance for its products, which is essential for generating significant revenue and profitability[151]. Employee and Operational Considerations - The company has implemented measures to ensure employee safety during the COVID-19 pandemic, including health screenings and remote work arrangements[130]. - The company emphasizes flexibility, psychological safety, and deliberate development in its employee experience strategy[129]. - The company has established a competitive compensation and benefits package to incentivize strong performance[129]. - The company is in the process of selling its oncology business to Servier for $1.8 billion in cash, with potential additional payments of $200 million and royalties of 5% and 15% on U.S. net sales of TIBSOVO® and vorasidenib, respectively[198]. - The company is committed to complying with both U.S. and EU regulatory requirements for product approvals, ensuring alignment with international standards[109].